QQ客服 官方微博 反馈留言

	Rosuvastatin Alleviates Diabetic Cardiomyopathy by Inhibiting NLRP3 Inflammasome and MAPK Pathways in a Type 2 Diabetes Rat Model
	Luo, Beibei; Li, Bo; Wang, Wenke; Liu, Xiangjuan; Liu, Xiaoman; Xia, Yanfei; Zhang, Cheng; Zhang, Yun; Zhang, Mingxiang; An, Fengshu 更多
刊名	CARDIOVASCULAR DRUGS AND THERAPY
	2014
卷号	28期号:1页码:33-43
关键词	DCM Rosuvastatin NLRP3 inflammasome Gene silencing MAPKs
DOI	10.1007/s10557-013-6498-1
URL标识	查看原文
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/4793958
专题	山东大学
作者单位	Shandong Uni
推荐引用方式 GB/T 7714	Luo, Beibei,Li, Bo,Wang, Wenke,et al. Rosuvastatin Alleviates Diabetic Cardiomyopathy by Inhibiting NLRP3 Inflammasome and MAPK Pathways in a Type 2 Diabetes Rat Model[J]. CARDIOVASCULAR DRUGS AND THERAPY,2014,28(1):33-43.
APA	Luo, Beibei.,Li, Bo.,Wang, Wenke.,Liu, Xiangjuan.,Liu, Xiaoman.,...&An, Fengshu 更多.(2014).Rosuvastatin Alleviates Diabetic Cardiomyopathy by Inhibiting NLRP3 Inflammasome and MAPK Pathways in a Type 2 Diabetes Rat Model.CARDIOVASCULAR DRUGS AND THERAPY,28(1),33-43.
MLA	Luo, Beibei,et al."Rosuvastatin Alleviates Diabetic Cardiomyopathy by Inhibiting NLRP3 Inflammasome and MAPK Pathways in a Type 2 Diabetes Rat Model".CARDIOVASCULAR DRUGS AND THERAPY 28.1(2014):33-43.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。